Standout Papers
Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Targeted therapies: a new generation of cancer treatments.
2008
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Cancer statistics, 2019
2019 Standout
A view on drug resistance in cancer
2019 StandoutNature
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population‐based cohort of elderly patients with non‐Hodgkin lymphoma
2008
CCR4 as a novel molecular target for immunotherapy of cancer
2006
Cancer Stem Cells: Are We Missing the Target?
2004
Direct conversion of human fibroblasts to multilineage blood progenitors
2010 Nature
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
2014
Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins
2016
Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
2007
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
2014
Chemotherapy and the war on cancer
2005 Standout
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial
2001
Immunity, Inflammation, and Cancer
2010 Standout
Monoclonal antibodies as therapeutic agents for cancer
2004
Cancer immunotherapy comes of age
2011 StandoutNature
Immunotherapy: past, present and future
2003
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
2006
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Review of clinical radioimmunotherapy
2006
Cancer-related inflammation
2008 StandoutNature
Infectious complications of monoclonal antibodies used in cancer therapy
2007
CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis
2015
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Tumour necrosis factor α: a potential target for the therapy of solid tumours
2003
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Immunopathogenesis of lymphoma: Focus on CCR4
2010
The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma
2004
Nanoparticle Delivery of Cancer Drugs
2011
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Carbon quantum dots and their applications
2014 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
The Tumor Lysis Syndrome
2011 Standout
Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study
2003
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.
1983
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
2003
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
2008
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
Spermidine in health and disease
2018 StandoutScience
Specific Recruitment of CC Chemokine Receptor 4–Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
2006
Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells
2012 StandoutNobel
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3
2011
Chimeric Antigen Receptor Therapy
2018 Standout
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
2004
Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation
2015 StandoutNobel
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
2010
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Emerging Targets in Photopharmacology
2016 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
Immune Therapy for Cancer
2008
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.
1987 StandoutNobel
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Works of P Lederlin being referenced
High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS).
1998
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.
1997
Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells
2003
Tumor necrosis factor α release is a major biological event associated with rituximab treatment
2001
Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study
2000
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
2000
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma
2002
Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study
2000
Acute Leukaemia after Prolonged Chlorambucil Treatment for Non-Malignant Disease: Report of a New Case and Literature Survey
1980
Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial.
2000